Robert W Postma - 24 Jun 2025 Form 4 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role
Director
Signature
/s/ Melinda Lackey, Attorney-in-Fact
Issuer symbol
TCRT
Transactions as of
24 Jun 2025
Net transactions value
+$64,822
Form type
4
Filing time
26 Jun 2025, 21:19:44 UTC
Previous filing
15 Apr 2025
Next filing
07 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Postma Robert W Director C/O ALAUNOS THERAPEUTICS, INC., 2617 BISSONNET ST, SUITE 233, HOUSTON /s/ Melinda Lackey, Attorney-in-Fact 26 Jun 2025 0001827847

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRT Common Stock Award $60,748 +20,804 +251% $2.92 29,083 13 Apr 2025 Direct
holding TCRT Common Stock 24 24 Jun 2025 By spouse's IRA
holding TCRT Common Stock 33,333 24 Jun 2025 By WaterMill Asset Management Corp. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRT Series A-1 Convertible Preferred Stock Purchase $1,380 +500 $2.76 500 11 Apr 2025 Common Stock 181,159 $2.76 By WaterMill Asset Management Corp. F1, F2, F3
transaction TCRT Series A-2 Convertible Preferred Stock Purchase $2,694 +600 $4.49 600 24 Jun 2025 Common Stock 133,630 $4.49 By Watermill Asset Management Corp F1, F2
holding TCRT Employee Stock Option (right to buy) 3,737 24 Jun 2025 Common Stock 3,737 $10.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.
F2 The preferred stock is perpetual and therefore has no expiration date.
F3 The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance.
F4 One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon.